STRaTEGY
Two Pillars for Evidence‑Based Therapies
Avextra focuses on two closely connected areas of expertise: the development of innovative cannabis‑based prescription medicines a robust clinical research program Together, these form the foundation for safe, scientifically validated use in clinical practice.
As a vertically integrated company, Avextra controls the entire value chain: from the plant to extraction, clinical development, and market introduction.
The two‑pillar strategy follows a clear objective: To transition cannabis‑based therapies from traditional experiential medicine into regulated, evidence‑based patient care.
Focus Indications:
Pain, neurology, palliative medicine
Region:
Core European markets
Development of Standardized, Cannabis‑Based Prescription Medicines
Development of standardized cannabis‑based prescription medicines with defined cannabinoid and terpene profiles – at pharmaceutical quality levels and with a clear focus on specific indications.
Standardized Extracts
EU‑GMP production
Prescribable
Clinical Studies
Planning and execution of randomized controlled trials as well as real‑world projects to demonstrate the efficacy, safety, and practical benefit of the preparations.
We are always looking to connect with those who share our vision. If you’re interested in receiving a detailed deck and discovering how you can be part of our success, please contact us today.
CONTaCT:
